VIP Nasal Spray for CIRS: What the Evidence Can Actually Decide

“Is there any harm in moving to VIP while you’re still completing other steps?”

One person asked that exact question during a MoldCo-hosted Reddit AMA. It brings the real decision into view: VIP has been used for CIRS, and this person wants to know whether a particular product fits now.

A completed protocol step can't answer that. VIP's published CIRS record isn't limited to one paper: additional studies have examined brain-volume and gene-expression changes during intranasal VIP treatment, and a 2017 paper reported intranasal VIP use by hundreds of physicians. Those studies broaden the record of documented use, but they don't answer this article's narrower question about timing or personal candidacy. The directly relevant 2013 study followed 20 selected patients who had already completed the authors' earlier treatment sequence. The study was open-label and uncontrolled. Compounded intranasal VIP for CIRS is also off-label, clinician-directed, and not an FDA-approved treatment.

So the study gives us a signal worth discussing. It doesn't give us a candidacy test.

What was actually studied

The published intervention was a compounded intranasal VIP preparation. Participants came from one specific CIRS-oriented clinical framework, had received extensive prior treatment, and still had persistent illness. That is a narrow research cohort, not a cross-section of everyone who suspects mold-related illness or has reached a similar point in an online protocol.

The authors reported favorable changes in symptoms and quality of life, along with laboratory and exercise-related pulmonary-pressure measures. Those observations belong beside the design limit. An open-label study without a concurrent control group can't establish that VIP caused the changes or predict which patient will benefit. An FDA evidence review identified the same problem: the small, uncontrolled study could not isolate a treatment effect with confidence.

The safety language needs the same discipline. The authors reported that no participant left because of an adverse effect and noted one transient laboratory change in the paper. Twenty selected people in an uncontrolled study can't establish general safety or reliable event rates. Limited reporting is a reason to define monitoring and reassessment before treatment, not a reason to assume that an individual response will be uncomplicated.

Selection is the hidden difficulty. The study didn't compare earlier use with later use, and it didn't test whether overlapping steps were safe. Prior treatment tells us who the researchers chose to observe. It doesn't create a universal timing rule for the patient sitting across from a clinician.

Study eligibility is a research description. Personal candidacy is a clinical judgment made with the patient in front of you.

The product name is part of the evidence

VIP is a naturally occurring peptide, but "VIP" on a label doesn't make every product or route equivalent to the preparation in the study. That evidence concerned an intranasal compounded product. It did not establish injectable, intravenous, homeopathic, or gray-market forms as interchangeable substitutes.

This distinction becomes urgent when cost interrupts care. One reader called the nasal product "impossible to take consistently due to cost" and said they switched products. That account proves financial pressure, not benefit or equivalence. When cost changes the product, route, or continuity of clinical care, it changes the decision itself.

Category 1 is easy to mistake for approval. As of May 14, 2026, vasoactive intestinal peptide appears on the FDA's Category 1 list of bulk substances under evaluation for Section 503A compounding. Category 1 is an evaluation and interim enforcement-policy category. It isn't approval, authorization, or evidence that the substance is safe and effective for CIRS.

Compounded drugs do not receive FDA premarket review for safety, effectiveness, or quality. Compounding can meet an important medical need, but the absence of that review makes exact product identity and clinician oversight more important. A shared ingredient name is not enough.

What needs to be clear before treatment

Start with the goal. "Try VIP" is a treatment idea, not a clinical goal. The clinician and patient should be able to name the problem they want the plan to address. That keeps a protocol milestone or test result from becoming a candidacy verdict.

Next comes fit. The published cohort had completed the authors' earlier sequence, which explains the context of the findings. It doesn't create a universal timing or overlap rule. For the person in front of them, the clinician should be able to explain why VIP is being considered now and what current concern could make it a poor fit.

Only then does the prescription enter the conversation. It should identify the exact compounded product and state the route clearly. Evidence for an intranasal preparation doesn't travel to another form just because the ingredient name matches. If cost could make the plan hard to continue, say so before it begins. Otherwise financial pressure can break continuity and push a patient toward an improvised substitution.

Before treatment, the patient and clinician should agree on what they will watch and when they will reassess. The plan also needs a clear point at which an unexpected response prompts contact. Symptoms and test results may inform that conversation, but neither can serve alone as proof of diagnosis, benefit, harm, or readiness.

The off-ramp matters just as much as the opening rationale. A plan should state when to end or reconsider the idea if the agreed signs of benefit don't appear, an unexpected response occurs, or new information changes the reason for treatment. That isn't pessimism. It keeps sunk cost and online success stories from taking over a medical judgment.

Continuity needs its own answer. If cost or access could interrupt the plan, bring that problem to the clinician before it becomes a crisis. The safer response to an impractical plan is a conversation about the plan, not an unsupported substitution based on a shared name.

Hold the decision to four clear answers: what the study found, why VIP might fit this person now, which exact product and route are under discussion, and what would prompt reassessment. A qualified clinician has to connect all four to the individual case. If one answer is vague, the next move is clarification, not inference.

Compounded intranasal VIP has a published CIRS evidence base that includes a small, directly relevant clinical study. That makes a careful conversation reasonable. It doesn't tell any individual that they need VIP, that now is the right time, or that another product is an acceptable substitute.

If you want clinician-guided help putting mold-related illness evaluation and treatment sequencing in context, MoldCo Care can help you prepare that conversation. It doesn't promise VIP eligibility, access, prescribing, or an outcome.

Medical disclaimer: Any health-related claims made on this site have not been evaluated by the Food and Drug Administration (FDA). The information provided on this site is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. MoldCo assumes no responsibility or liability for any errors or omissions in the content of the references, nor for any actions taken in reliance thereon.